AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6315514
Drug: Standard dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dietary advice (12.4 g dietary fibre/24 h)
Trial: 30625398
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) with adjunct antimicrobial photodynamic therapy (aPDT)
Trial: 28642208
Drug: Imagery-enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery-enhanced cognitive behavioral group therapy (IE-CBGT)
Trial: 28642208
Drug: Verbally-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbally-based cognitive behavioral group therapy (VB-CBGT)
Trial: 25680595
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) with oxaliplatin 130 mg/m² on day 1 and S1 at 40 mg/m² twice daily on days 1‐14, followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m² on days 1 and 21 and S1 30 mg/m² twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A)
Trial: 25680595
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) followed by esophagectomy without ICT (arm B)
Trial: 25680595
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) with oxaliplatin and S1 (arm A)
Trial: 25680595
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) without ICT (arm B)
Trial: 16013776
Drug: FDC formulations
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC formulations containing rifampicin, isoniazid, and ethambutol hydrochloride
Trial: 12204509
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg and cobalamin 400 microg daily
Trial: 10476895
Drug: GBA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBA group (polylactide bioabsorbable membrane, DFDBA plus antibiotics)
Trial: 6299752
Drug: Mianserin (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (acute and chronic administration)
Trial: 6299752
Drug: Mianserin (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (acute administration)
Trial: 30272851
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule of Bifidobacterium longum and Lactobacillus acidophilus (2 × 10^7 CFU/day)
Trial: 30272851
Drug: Prebiotic (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (10 g/day inulin)
Trial: 30272851
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of probiotic and prebiotic
Trial: 26386707
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy (methotrexate and celecoxib)
Trial: 8716209
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy
Trial: 23193218
Drug: Mindfulness‐Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐Based Cognitive Therapy (MBCT)
Trial: 16303697
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements (1 mg/kg/d) from 4‐9 mo of age
Trial: 16303697
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements from 6‐9 mo
Trial: 9856716
Drug: Tenoxicam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (2 mg) with lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Trial: 8669876
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of fibrin glue (Tissucol) applied to the wound cavity
Trial: 692548
Drug: Low compliance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low compliance with treatment
Trial: 22506692
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% tranexamic acid
Trial: 20688744
Drug: Saffron 20
RxNorm normalized name: SAFFRON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron 20 mg/d
Trial: 12949718
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg daily for >14 days
Trial: 10566707
Drug: Sumatriptan 6
RxNorm normalized name: sumatriptan 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 6 mg subcutaneous (s.c.)
Trial: 8678099
Drug: Cefepime 1
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1 g every 12 hours
Trial: 8678099
Drug: Ceftazidime 1
RxNorm normalized name: ceftazidime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1 g every 8 hours
Trial: 1985504
Drug: ORG 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 9426 (up to 5 maintenance doses)
Trial: 1985504
Drug: ORG 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 9426 (doses used in the study)
Trial: 6684719
Drug: Aztreonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1 g every 8 hours for 5 to 10 days)
Trial: 6684719
Drug: Cefamandole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1 g every 8 hours for 5 to 10 days)
Trial: 29858418
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture and real medicine (topiramate)
Trial: 18548084
Drug: Oral patterned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral patterned entrainment intervention (synthetically patterned orocutaneous pulse trains through a pneumatically controlled silicone pacifier)
Trial: 18548084
Drug: Oral patterned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral patterned entrainment intervention
Trial: 15935981
Drug: High-dose hGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hGH (16 U/d) for nine days
Trial: 12796368
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human LIF (rhLIF) at doses of 0.25‐16.0 micro g/kg/day or 4.0 micro g/kg three times daily for 7 days
Trial: 12796368
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human LIF (rhLIF) at doses of 0.25‐8.0 micro g/kg/day once daily for 14 days or 4.0 micro g/kg three times daily for 7 days
Trial: 12796368
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human LIF (rhLIF) at doses of >/=4.0 micro g/kg/day
Trial: 12796368
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human LIF (rhLIF) at higher doses
Trial: 8393398
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, four times daily)
Trial: 8393398
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (2 mg, four times daily)
Trial: 3575558
Drug: Lithium (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (mean plasma level: 0.65 mmol/l)
Trial: 29175417
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype for the ESRRB (rs1676303) gene
Trial: 23278618
Drug: 0.15% ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ivermectin lotion
Trial: 23278618
Drug: 0.25% ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ivermectin lotion
Trial: 23113480
Drug: 0.5% ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ivermectin lotion
Trial: 18452785
Drug: CCM ON
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCM ON therapy for 3 months
Trial: 18452785
Drug: CCM OFF
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCM OFF therapy for 3 months
Trial: 12939429
Drug: Oral modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral modified cobratoxin
Trial: 10845438
Drug: Ambroxol treatment
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol treatment (30 mg kg(‐1) over the first 5 days)
Trial: 8403133
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg orally
Trial: 31023843
Drug: Gefapixant 100
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 100 mg
Trial: 24395447
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg daily for 2 years
Trial: 24395447
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (A) 40 mg/m2 and Cyclophosphamide (C) 500 mg/m2 plus Tamoxifen (ACT)
Trial: 2172393
Drug: Oka/Merck varicella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka/Merck varicella vaccine (lot C-K472) with 950 pfu and relative antigen content of 1.0
Trial: 2172393
Drug: Oka/Merck varicella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka/Merck varicella vaccine with 1140 pfu/1.7 relative antigen or 1145 pfu/1.6 relative antigen
Trial: 2172393
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Oka/Merck varicella vaccine with 950 pfu/1.0 relative antigen content)
Trial: 30932775
Drug: Lutein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein complex supplementation (10 mg lutein, 500 mg ascorbic acid, 364 mg tocopherols, 2.5 mg carnosic acid, 2 mg zeaxanthin, 2 mg copper)
Trial: 24418801
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Trial: 24418801
Drug: Placebo low-level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Trial: 22079773
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg XR‐NTX
Trial: 22079773
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg XR‐NTX
Trial: 22079773
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg XR‐NTX
Trial: 19330703
Drug: 3 hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 hourly feeds
Trial: 19330703
Drug: 2 hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hourly feeds
Trial: 7814759
Drug: Transmandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmandibular implant
Trial: 15346755
Drug: Augmentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation of the mandible with an autologous bone graft followed by placement of 4 endosseous implants
Trial: 15346755
Drug: Placement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of 4 endosseous implants only
Trial: 11224756
Drug: Iomeprol-containing liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol-containing liposomal formulations
Trial: 9586887
Drug: Treatments containing
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments containing interferon (IFN)
Trial: 9586887
Drug: Treatments without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments without interferon (IFN)
Trial: 2719175
Drug: Histamine chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine chloride control (10 mg/ml)
Trial: 24746974
Drug: Lupin protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupin protein (LP) 25 g/d
Trial: 23054692
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg empagliflozin q.d. for 5 days
Trial: 23054692
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 50 mg empagliflozin q.d. and 100 mg sitagliptin q.d. over 5 days
Trial: 23054692
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin q.d. for 5 days
Trial: 15601268
Drug: Pethidine 15
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 15 mg with a 10‐min lockout
Trial: 10506687
Drug: Ocular spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular spray administration
Trial: 10506687
Drug: Ocular drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular drops administration
Trial: 7503039
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with a 30 mW gallium-arsenide-aluminium (830 nm) diode laser probe for 15, 30, and 60 seconds.
Trial: 7503039
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 30 seconds.
Trial: 2020093
Drug: Midazolam 4
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 4 mg i.m. (Group M)
Trial: 2020093
Drug: Hydroxyzine 50
RxNorm normalized name: hydroxyzine hydrochloride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 50 mg i.m. (Group H)
Trial: 2020093
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg and pentazocine 6 mg for intraoperative sedation (both groups)
Trial: 2020093
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and pentazocine maintenance doses (both groups)
Trial: 6121709
Drug: Somatostatin with
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin with prior indomethacin administration
Trial: 25791145
Drug: Duloxetine (30‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30‐120 mg daily)
Trial: 23397566
Drug: Antibiotic-impregnated catheters
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated catheters (Bactiseal(®))
Trial: 17159373
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO) - Group A: 2.2 bar for 60 min bottom time
Trial: 17159373
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO) - Group B: 2.5 bar for 60 min bottom time
Trial: 15602194
Drug: RIX4414 live
RxNorm normalized name: HUMAN ROTAVIRUS A TYPE G1P(8) STRAIN RIX4414 LIVE ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 live attenuated human rotavirus vaccine
Trial: 11529281
Drug: omalizumab during
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: omalizumab during the steroid-reduction phase
Trial: 9753250
Drug: rebamipide 100
RxNorm normalized name: Rebamipide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide 100 mg thrice daily for eight weeks
Trial: 9753250
Drug: teprenone 50
RxNorm normalized name: teprenone
DrugBank: Teprenone (DB15955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teprenone 50 mg thrice daily for eight weeks
Trial: 7877584
Drug: SST+MLD (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST+MLD (standard surgical treatment plus medicinal lymph node dissection)
Trial: 7877584
Drug: SST only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST only (standard surgical treatment)
Trial: 2899718
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human tissue‐type plasminogen activator (rt‐PA)
Trial: 27864462
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy (IAT) for grade 3 collateral status
Trial: 27864462
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy (IAT) for grade 2 collateral status
Trial: 27864462
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy (IAT) for grade 1 collateral status
Trial: 26334726
Drug: Fixed-dose intravenous
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose intravenous combination of 3 mg/mL ibuprofen and 10 mg/mL paracetamol
Trial: 26334726
Drug: Oral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of the same doses of ibuprofen and paracetamol
Trial: 16611155
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents to prevent aneurysm expansion and rupture
Trial: 9812477
Drug: Salmonella typhi
RxNorm normalized name: Salmonella Typhi Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmonella typhi Vi capsular polysaccharide vaccine (Vi)
Trial: 9812477
Drug: Diluted solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted solution (DS) of Vi (placebo)
Trial: 3034469
Drug: Cilazapril 4
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 4 mg
Trial: 7898090
Drug: Cilazapril (1.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (1.25, 3.75, 10, and 30 mg)
Trial: 31241192
Drug: Nurse-led asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led asthma management and routine treatment measures (including inhaled corticosteroids)
Trial: 24733191
Drug: MTX 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX 12.5 mg once a week
Trial: 24733191
Drug: TwHF 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF 20 mg three times a day
Trial: 24733191
Drug: MTX+TwHF combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX+TwHF combination
Trial: 23141837
Drug: Budesonide 400μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400μg/day plus immunotherapy
Trial: 21705894
Drug: Daily evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily evaluation and spontaneous breathing test with 10 cm H2O pressure support and 5 cm H2O positive end-expiratory pressure for 2 hours
Trial: 6359996
Drug: Antibody detection
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody detection by enzyme‐linked immunosorbent assay
Trial: 30046691
Drug: Idarucizumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (1, 2, 4, or 8 g)
Trial: 30046691
Drug: Idarucizumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (1, 2, 4, or 5 g) with dabigatran (220 mg bid)
Trial: 22813840
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus aripiprazole
Trial: 19318984
Drug: Atorvastatin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (in amlodipine-based therapy)
Trial: 19318984
Drug: Atorvastatin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (in atenolol-based therapy)
Trial: 17728418
Drug: Intensive psychosocial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive psychosocial intervention (30 sessions over 9 months of interpersonal and social rhythm therapy, cognitive behavior therapy [CBT], or family‐focused therapy)
Trial: 17728418
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (a 3‐session psychoeducational treatment)
Trial: 15637976
Drug: Manual toothbrushing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrushing coupled with daily flossing (positive control)
Trial: 11431729
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg bolus plus 0.05 mg/kg.min for 120 minutes)
Trial: 9736100
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (home care treatment)
Trial: 8303937
Drug: DTP whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP whole‐cell pertussis vaccine